Physician profile
Bridget E Mcilwee
NPI 1982040069
$786.63
in general payments reported to CMS, 2019-2025
11 companies · $402 in 2025
The $402 reported for 2025 was less than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $200 · 2022: $53.89 · 2023: $63.89 · 2024: $67.43 · 2025: $402.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $533.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $533.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $231.78 | 2025 | Nemluvio |
| Mayne Pharma Commercial LLC | $199.68 | 2019 | |
| Abbvie INC. | $89.14 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $55.12 | 2023-2025 | Dupixent |
| Kerecis Limited | $53.89 | 2022 | |
| Novartis Pharmaceuticals Corporation | $49.08 | 2023-2025 | |
| Organon LLC | $32.35 | 2025 | Hadlima |
| Lilly USA, LLC | $24.27 | 2025 | Ebglyss |
| Organogenesis INC. | $18.99 | 2024 | |
| Incyte Corporation | $16.94 | 2025 | Opzelura |
| Smith+Nephew, INC. | $15.39 | 2023 | Grafix Pl |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bridget Mcilwee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.